These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 28764718)
1. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718 [TBL] [Abstract][Full Text] [Related]
2. c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer. Lee KS; Kwak Y; Nam KH; Kim DW; Kang SB; Choe G; Kim WH; Lee HS PLoS One; 2015; 10(10):e0139727. PubMed ID: 26426996 [TBL] [Abstract][Full Text] [Related]
3. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target. Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290 [TBL] [Abstract][Full Text] [Related]
4. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers. Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259 [TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Seo AN; Park KU; Choe G; Kim WH; Kim DW; Kang SB; Lee HS Tumour Biol; 2015 Dec; 36(12):9813-21. PubMed ID: 26159851 [TBL] [Abstract][Full Text] [Related]
6. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134 [TBL] [Abstract][Full Text] [Related]
7. Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method. Higaki E; Kuwata T; Nagatsuma AK; Nishida Y; Kinoshita T; Aizawa M; Nitta H; Nagino M; Ochiai A Gastric Cancer; 2016 Jan; 19(1):63-73. PubMed ID: 25487305 [TBL] [Abstract][Full Text] [Related]
8. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer. Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009 [TBL] [Abstract][Full Text] [Related]
9. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441 [TBL] [Abstract][Full Text] [Related]
11. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814 [TBL] [Abstract][Full Text] [Related]
12. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. Polónia A; Leitão D; Schmitt F Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674 [TBL] [Abstract][Full Text] [Related]
13. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653 [TBL] [Abstract][Full Text] [Related]
14. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. Sapino A; Maletta F; Verdun di Cantogno L; Macrì L; Botta C; Gugliotta P; Scalzo MS; Annaratone L; Balmativola D; Pietribiasi F; Bernardi P; Arisio R; Viberti L; Guzzetti S; Orlassino R; Ercolani C; Mottolese M; Viale G; Marchiò C Oncologist; 2014 Nov; 19(11):1118-26. PubMed ID: 25323485 [TBL] [Abstract][Full Text] [Related]
15. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline. Kong H; Bai Q; Li A; Zhou X; Yang W Diagn Pathol; 2022 Jan; 17(1):5. PubMed ID: 34996485 [TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759 [TBL] [Abstract][Full Text] [Related]
17. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience. Varga Z; Noske A PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856 [No Abstract] [Full Text] [Related]
19. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Park K; Kwak K; Kim J; Lim S; Han S Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569 [TBL] [Abstract][Full Text] [Related]
20. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer. Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]